Table 1.
Patient demographic and disease characteristics
| All patientsa | Etanercept | Adalimumab | Ustekinumab | |
|---|---|---|---|---|
| n (%) | 2152 | 517 (24·0) | 1239 (57·6) | 396 (18·4) |
| Demographic characteristics | ||||
| Age (years), mean ± SD | 45·2 ± 12·4 | 45·1 ± 12·1 | 44·8 ± 12·4 | 46·7 ± 12·3 |
| Female | 847 (39·4) | 217 (42·0) | 485 (39·1) | 145 (36·6) |
| BMI category, kg m−2 | ||||
| Nonobese (BMI < 30) | 1011 (47·0) | 261 (50·5) | 582 (47·0) | 168 (42·4) |
| Obese (BMI ≥ 30) | 1009 (46·9) | 226 (43·7) | 590 (47·6) | 193 (48·7) |
| Missing | 132 (6·1) | 30 (5·8) | 67 (5·4) | 35 (8·8) |
| Smoking status | ||||
| Never smoked | 599 (27·8) | 132 (25·5) | 358 (28·9) | 109 (27·5) |
| Ex‐smoker | 648 (30·1) | 131 (25·3) | 395 (31·9) | 122 (30·8) |
| Current smoker | 532 (24·7) | 130 (25·2) | 293 (23·7) | 109 (27·5) |
| Missing | 373 (17·3) | 124 (24·0) | 193 (15·6) | 56 (14·1) |
| Psoriatic arthritis/comorbidities | ||||
| Psoriatic arthritis | 527 (24·5) | 129 (25·0) | 314 (25·3) | 84 (21·2) |
| No comorbidities | 572 (26·6) | 140 (27·1) | 328 (26·5) | 104 (26·3) |
| 1–2 comorbidities | 1042 (48·4) | 259 (50·1) | 623 (50·3) | 160 (40·4) |
| 3–4 comorbidities | 405 (18·8) | 96 (18·6) | 222 (17·9) | 87 (22·0) |
| ≥ 5 comorbidities | 133 (6·2) | 22 (4·3) | 66 (5·3) | 45 (11·4) |
| Disease | ||||
| Disease duration, (years) mean ± SD | 22·4 ± 12·1 | 22·9 ± 12·1 | 22·3 ± 12·1 | 22·0 ± 12·1 |
| Age of onset, (years) mean ± SD | 22·9 ± 12·9 | 22·2 ± 12·4 | 22·6 ± 12·5 | 24·8 ± 14·5 |
| Baseline DLQI, median (IQR) (n = 1804) | 18 (13–24) | 18 (13–24) | 18 (13–23) | 19 (13–24) |
| Baseline EQ‐5D, median (IQR) (n = 1618) | 0·73 (0·59–0·80) | 0·73 (0·52–0·80) | 0·73 (0·62–0·80) | 0·73 (0·59–0·80) |
| Unstable psoriasis | 268 (12·5) | 72 (13·9) | 146 (11·8) | 50 (12·6) |
| Medication history | ||||
| Biologic naïve | 1736 (80·7) | 481 (93·0) | 1029 (83·1) | 226 (57·1) |
| Concomitant methotrexateb | 358 (16·6) | 82 (15·9) | 210 (17·0) | 66 (16·7) |
| Concomitant ciclosporinb | 149 (6·9) | 42 (8·1) | 80 (6·5) | 27 (6·8) |
| Concomitant other systemicsb , c | 95 (4·4) | 23 (4·5) | 45 (3·6) | 27 (6·8) |
Data are presented as n (%) unless otherwise stated. BMI, body mass index; IQR, interquartile range; DLQI, Dermatology Life Quality Index; EQ‐5D, EuroQol‐5D. aHad a complete DLQI (only one question left unanswered) and/or EQ‐5D (no question left unanswered) questionnaire recorded within 6 months prior to the start of the index biological therapy, as well as had another complete DLQI and/or EQ‐5D questionnaire recorded within 4–8 months (representing the 6‐month follow‐up) and/or 10–14 months (representing the 12‐month follow‐up) after the start of the index biological therapy. bEver used conventional systemic therapies concomitantly with a biological therapy throughout the study period of 12 months. cIncludes any of acitretin, fumaric acid esters and hydroxycarbamide.